

Jafna L Cox

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1393273/publications.pdf>

Version: 2024-02-01

120
papers

7,998
citations

94381

37
h-index

48277

88
g-index

121
all docs

121
docs citations

121
times ranked

9098
citing authors

#	ARTICLE	IF	CITATIONS
1	Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Update 2020 â€” ADDENDUM. Canadian Journal of Neurological Sciences, 2023, 50, 481-481.	0.3	3
2	Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Update 2020. Canadian Journal of Neurological Sciences, 2022, 49, 315-337.	0.3	57
3	The association between anticoagulation and adverse outcomes after a positive SARS-CoV-2 test among older outpatients: A population-based cohort study. Thrombosis Research, 2022, 211, 114-122.	0.8	5
4	Rhythm Control Vs Rate Control in a Contemporary Ambulatory Atrial Fibrillation Cohort: Post Hoc Analysis of the IMPACT-AF Trial. CJC Open, 2022, 4, 551-557.	0.7	4
5	Temporal Trends in Population Rates of Incident Atrial Fibrillation and Atrial Flutter Hospitalizations, Stroke Risk, and Mortality Show Decline in Hospitalizations. Canadian Journal of Cardiology, 2021, 37, 310-318.	0.8	3
6	Detecting Patients With Nonvalvular Atrial Fibrillation and Atrial Flutter in the Canadian Primary Care Sentinel Surveillance Network: First Steps. CJC Open, 2021, 3, 367-371.	0.7	1
7	Surveillance for Outcomes Selected as Atrial Fibrillation Quality Indicators in Canada: 10-Year Trends in Stroke, Major Bleeding, and Heart Failure. CJC Open, 2021, 3, 609-618.	0.7	1
8	Colchicine for Prevention of Atherothrombotic Events in Patients With Coronary Artery Disease: Review and Practical Approach for Clinicians. Canadian Journal of Cardiology, 2021, 37, 1837-1845.	0.8	8
9	Patientâ€”Reported Outcomes and Patientâ€”Reported Experience of Patients With Atrial Fibrillation in the IMPACTâ€”AF Clinical Trial. Journal of the American Heart Association, 2021, 10, e019783.	1.6	4
10	Lessons learned from Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF): a pragmatic clinical trial of computerized decision support in primary care. Trials, 2021, 22, 531.	0.7	2
11	The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2020, 36, 1847-1948.	0.8	313
12	High-Sensitivity Cardiac Troponinâ€”Optimizing the Diagnosis of Acute Myocardial Infarction/Injury in Women (CODE-MI): Rationale and design for a multicenter, stepped-wedge, cluster-randomized trial. American Heart Journal, 2020, 229, 18-28.	1.2	11
13	Management of Acute Coronary Syndromes Beyond the First Year: A Canadian Clinical Practice Survey. CJC Open, 2020, 2, 619-624.	0.7	0
14	Canadian Stroke Best Practice Recommendations, seventh edition: acetylsalicylic acid for prevention of vascular events. Cmaj, 2020, 192, E302-E311.	0.9	13
15	Assessment of an Algorithm for Prescription of Oral Anticoagulation for Patients With Atrial Fibrillation in Emergency Departments. JAMA Network Open, 2020, 3, e200306.	2.8	3
16	Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF): A cluster randomized trial of a computerized clinical decision support tool. American Heart Journal, 2020, 224, 35-46.	1.2	27
17	An Update on the Development and Feasibility Assessment of Canadian Quality Indicators for Atrial Fibrillation and Atrial Flutter. CJC Open, 2019, 1, 198-205.	0.7	9
18	Use of Administrative Data to Monitor Cardiac Implantable Electronic Device Complications. Canadian Journal of Cardiology, 2019, 35, 100-103.	0.8	18

#	ARTICLE	IF	CITATIONS
19	Association Between Patient and Physician Sex and Physician-Estimated Stroke and Bleeding Risks in Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2019, 35, 160-168.	0.8	4
20	Where you Live in Nova Scotia Can Significantly Impact Your Access to Lifesaving Cardiac Care: Access to Invasive Care Influences Survival. <i>Canadian Journal of Cardiology</i> , 2018, 34, 202-208.	0.8	6
21	Optimizing primary care management of atrial fibrillation: The rationale and methods of the Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF) study. <i>American Heart Journal</i> , 2018, 201, 149-157.	1.2	23
22	Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017. <i>International Journal of Stroke</i> , 2018, 13, 420-443.	2.9	175
23	2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1371-1392.	0.8	195
24	Factors associated with door-in to door-out delays among ST-segment elevation myocardial infarction (STEMI) patients transferred for primary percutaneous coronary intervention: a population-based cohort study in Ontario, Canada. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 204.	0.7	11
25	Renal Function Estimation Equations and Drug Dosing: Things Are Not Always What They Seem. <i>Canadian Journal of Cardiology</i> , 2018, 34, 965-967.	0.8	2
26	Why We Need More and Better Cardiovascular Disease Quality Indicators. <i>Canadian Journal of Cardiology</i> , 2017, 33, 416-419.	0.8	1
27	Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017, 120, 582-587.	0.7	8
28	Canadian Cardiovascular Society/Canadian Heart Rhythm Society 2016 Implantable Cardioverter-Defibrillator Guidelines. <i>Canadian Journal of Cardiology</i> , 2017, 33, 174-188.	0.8	84
29	2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1170-1185.	0.8	243
30	Sex Differences in Clinical Outcomes After Premature Acute Coronary Syndrome. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1447-1453.	0.8	42
31	Oral Anticoagulation for Stroke Prevention in Canadian Practice: Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF) Registry*. <i>Canadian Journal of Cardiology</i> , 2016, 32, 204-210.	0.8	9
32	Sex Versus Gender-Related Characteristics. <i>Journal of the American College of Cardiology</i> , 2016, 67, 127-135.	1.2	228
33	The Development and Feasibility Assessment of Canadian Quality Indicators for Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1566-1569.	0.8	11
34	Canadian Cardiovascular Society Quality Indicators for Heart Failure. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1038.e5-1038.e9.	0.8	13
35	The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation Patients. <i>Canadian Journal of Cardiology</i> , 2016, 32, 336-343.	0.8	14
36	A Digital Health System to Assist Family Physicians to Safely Prescribe NOAC Medications. <i>Studies in Health Technology and Informatics</i> , 2016, 228, 519-23.	0.2	5

#	ARTICLE	IF	CITATIONS
37	Harnessing the power of real-life data. <i>European Heart Journal Supplements</i> , 2015, 17, D9-D14.	0.0	6
38	Achieving access: addressing the needs of payors and health technology assessment agencies: Figure 1. <i>European Heart Journal Supplements</i> , 2015, 17, D15-D20.	0.0	5
39	The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1207-1218.	0.8	43
40	Effective practical management of patients with atrial fibrillation when using new oral anticoagulants. <i>Annals of Medicine</i> , 2015, 47, 278-288.	1.5	0
41	Practical Management of Stroke Prevention in Patients with Atrial Fibrillation and Renal Impairment Receiving Newer Oral Anticoagulants: Focus on Rivaroxaban. <i>Journal of General Practice (Los Angeles)</i> , 2014, 11, 107-114.	0.7	14
42	2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1114-1130.	0.8	382
43	Aligning Health Care Policy With Evidence-Based Medicine: The Case for Funding Direct Oral Anticoagulants in Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1245-1248.	0.8	11
44	Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology/Canadian Society of Cardiac Surgery Position Statement on Revascularization of Multivessel Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1482-1491.	0.8	48
45	Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Implementation. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1346-1360.	0.8	22
46	A Novel Approach to Cardiovascular Health By Optimizing Risk Management (ANCHOR): Behavioural Modification in Primary Care Effectively Reduces Global Risk. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1400-1407.	0.8	18
47	Adopting the New Anticoagulants: All Aboard or All in Good Time?. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1295-1298.	0.8	3
48	Use of Primary Prevention Implantable Cardioverter-Defibrillators in a Population-Based Cohort Is Associated With a Significant Survival Benefit. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 706-713.	2.1	29
49	Using OWL Ontologies for Clinical Guidelines Based Comorbid Decision Support. , 2012, , .		9
50	Should all patients be treated with an angiotensin-converting enzyme inhibitor after coronary artery bypass graft surgery? The impact of angiotensin-converting enzyme inhibitors, statins, and β -blockers after coronary artery bypass graft surgery. <i>American Heart Journal</i> , 2011, 162, 836-843.	1.2	16
51	Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Catheter Ablation for Atrial Fibrillation/Atrial Flutter. <i>Canadian Journal of Cardiology</i> , 2011, 27, 60-66.	0.8	87
52	Cardiometabolic Risk in Canada: A Detailed Analysis and Position Paper by the Cardiometabolic Risk Working Group. <i>Canadian Journal of Cardiology</i> , 2011, 27, e1-e33.	0.8	138
53	Identification and Management of Cardiometabolic Risk in Canada: A Position Paper by the Cardiometabolic Risk Working Group (Executive Summary). <i>Canadian Journal of Cardiology</i> , 2011, 27, 124-131.	0.8	48
54	A Novel Approach to Cardiovascular Health by Optimizing Risk Management (ANCHOR): A Primary Prevention Initiative Examining the Impact of Health Risk Factor Assessment and Management on Cardiac Wellness. <i>Canadian Journal of Cardiology</i> , 2011, 27, 809-817.	0.8	14

#	ARTICLE	IF	CITATIONS
55	Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 2: ST-Segment Elevation Myocardial Infarction. Canadian Journal of Cardiology, 2011, 27, S402-S412.	0.8	33
56	Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 1: Non-ST-Segment Elevation ACS. Canadian Journal of Cardiology, 2011, 27, S387-S401.	0.8	29
57	New Anticoagulants for Atrial Fibrillation: The Beginning of a A New Era in Stroke Prevention. Canadian Journal of Neurological Sciences, 2011, 38, 777-782.	0.3	0
58	The potential economic impact of restricted access to angiotensin-receptor blockers. Cmaj, 2011, 183, E180-E186.	0.9	8
59	Secular trends in acute coronary syndrome hospitalization from 1994 to 2005. Canadian Journal of Cardiology, 2010, 26, 129-134.	0.8	38
60	CANadian Network and Centre for Trials Internationally (CANNeCTIN): A national network for Canadian-led trials in cardiovascular diseases and diabetes mellitus. Canadian Journal of Cardiology, 2010, 26, 353-358.	0.8	10
61	ICONS: Managing Care and Costs: The Sustained Cost Impact of Reduced Hospitalizations in a Partnership-Measurement Model of Disease Management. Healthcare Quarterly, 2010, 13, 30-39.	0.7	2
62	Long-term trends in use of and expenditures for cardiovascular medications in Canada. Cmaj, 2009, 181, E19-E28.	0.9	24
63	The impact of statins on health services utilization and mortality in older adults discharged from hospital with ischemic heart disease: a cohort study. BMC Health Services Research, 2009, 9, 198.	0.9	12
64	The effect of place of residence on access to invasive cardiac services following acute myocardial infarction. Canadian Journal of Cardiology, 2009, 25, 207-212.	0.8	37
65	Heart failure clinics are associated with clinical benefit in both tertiary and community care settings: Data from the Improving Cardiovascular Outcomes in Nova Scotia (ICONS) registry. Canadian Journal of Cardiology, 2009, 25, S306-S311.	0.8	35
66	Drug Reimbursement Policies in Canada – Need for Improved Access to Critical Therapies. Annals of Pharmacotherapy, 2008, 42, 869-873.	0.9	7
67	Cardiovascular Outcomes after a Change in Prescription Policy for Clopidogrel. New England Journal of Medicine, 2008, 359, 1802-1810.	13.9	74
68	Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures. Cmaj, 2008, 178, 405-409.	0.9	73
69	Development of end stage renal disease following an acute cardiac event. Kidney International, 2008, 74, 356-363.	2.6	2
70	Optimizing Healthcare at the Population Level: Results of the Improving Cardiovascular Outcomes in Nova Scotia Partnership. Healthcare Quarterly, 2008, 11, 28-41.	0.7	8
71	A comprehensive view of sex-specific issues related to cardiovascular disease. Cmaj, 2007, 176, S1-S44.	0.9	348
72	Quality indicators for cardiovascular primary care. Canadian Journal of Cardiology, 2007, 23, 383-388.	0.8	30

#	ARTICLE	IF	CITATIONS
73	The impact of warfarin use on clinical outcomes in atrial fibrillation: A population-based study. Canadian Journal of Cardiology, 2007, 23, 457-461.	0.8	26
74	The Effect of Spironolactone Use on Heart Failure Mortality: A Population-Based Study. Journal of Cardiac Failure, 2007, 13, 165-169.	0.7	17
75	Unequal access to interventional cardiac care in Nova Scotia in patients with acute myocardial infarction complicated by cardiogenic shock. Canadian Journal of Cardiology, 2006, 22, 331-335.	0.8	5
76	Anemia is an independent risk for mortality after acute myocardial infarction in patients with and without diabetes. Cardiovascular Diabetology, 2006, 5, 8.	2.7	46
77	Improved prediction of early-onset coronary artery disease using APOE ϵ 4, BChE-K, PPAR γ 2 Pro12 and ENOS T-786C in a polygenic model. Clinical Biochemistry, 2006, 39, 109-114.	0.8	30
78	Quality indicators for cardiac care: national standards in a community context. Journal of Health Services Research and Policy, 2006, 11, 5-12.	0.8	6
79	Trends in event rate and case fatality of patients hospitalized with myocardial infarction between 1984 and 2001 This paper is one of a selection of papers published in this Special Issue, entitled Young Investigator's Forum.. Canadian Journal of Physiology and Pharmacology, 2006, 84, 121-127.	0.7	5
80	Relative Fitness and Frailty of Elderly Men and Women in Developed Countries and Their Relationship with Mortality. Journal of the American Geriatrics Society, 2005, 53, 2184-2189.	1.3	486
81	Outcomes of Acute Coronary Syndrome in a Large Canadian Cohort: Impact of Chronic Renal Insufficiency, Cardiac Interventions, and Anemia. American Journal of Kidney Diseases, 2005, 46, 845-855.	2.1	97
82	Impact of a patient decision aid on care among patients with nonvalvular atrial fibrillation: a cluster randomized trial. Cmaj, 2005, 173, 496-501.	0.9	80
83	Acute treatment of myocardial infarction in Canada 1999-2002. Canadian Journal of Cardiology, 2005, 21, 145-52.	0.8	18
84	Population-based evaluation of the management of antithrombotic therapy for atrial fibrillation. Canadian Journal of Cardiology, 2005, 21, 257-66.	0.8	10
85	Pharmacological treatment of congestive heart failure in Canada: a description of care in five provinces. Canadian Journal of Cardiology, 2005, 21, 337-43.	0.8	15
86	What has trust got to do with it? Cardiac risk reduction and family physicians' discussions of evidence-based recommendations. Health, Risk and Society, 2004, 6, 239-255.	0.9	3
87	The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada. Cmaj, 2004, 170, 1678-1686.	0.9	1,729
88	A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643]. BMC Cardiovascular Disorders, 2004, 4, 5.	0.7	11
89	Evidence-based cardiovascular care in the community: A population-based cross-sectional study. BMC Family Practice, 2004, 5, 6.	2.9	6
90	Predictors of intracranial hemorrhage with fibrinolytic therapy in unselected community patients: a report from the FASTRAK II project. American Heart Journal, 2004, 148, 86-91.	1.2	46

#	ARTICLE	IF	CITATIONS
91	Evidence-based cardiovascular care. Family physicians' views of obstacles and opportunities. Canadian Family Physician, 2004, 50, 1397-405.	0.1	6
92	Anticoagulation in atrial fibrillation. Is there a gap in care for ambulatory patients?. Canadian Family Physician, 2004, 50, 1244-50.	0.1	6
93	Secondary prevention after acute myocardial infarction in four Canadian provinces, 1997-2000. Canadian Journal of Cardiology, 2004, 20, 61-7.	0.8	28
94	Cardiac procedures after an acute myocardial infarction across nine Canadian provinces. Canadian Journal of Cardiology, 2004, 20, 491-500.	0.8	22
95	Regional outcomes of heart failure in Canada. Canadian Journal of Cardiology, 2004, 20, 599-607.	0.8	43
96	Fibrinolytic therapy in acute myocardial infarction: time to treatment in Canada. Canadian Journal of Cardiology, 2004, 20, 801-5.	0.8	5
97	Population rates of hospitalization for atrial fibrillation/flutter in Canada. Canadian Journal of Cardiology, 2004, 20, 869-76.	0.8	58
98	Use of complementary and alternative medical therapies in patients with cardiovascular disease. American Heart Journal, 2003, 145, 806-812.	1.2	89
99	Undocumented patient information: an impediment to quality of care. American Journal of Medicine, 2003, 114, 211-216.	0.6	48
100	Improving Cardiovascular Outcomes in Nova Scotia (ICONS): A Successful Public-Private Partnership in Primary Healthcare. Healthcare Quarterly, 2003, 6, 32-38.	0.7	6
101	CCORT/CCS quality indicators for acute myocardial infarction care. Canadian Journal of Cardiology, 2003, 19, 38-45.	0.8	39
102	Physician specialty and quality of care for CHF: different patients or different patterns of practice?. Canadian Journal of Cardiology, 2003, 19, 371-7.	0.8	7
103	Identifying opportunities to address the congestive heart failure burden: the Improving Cardiovascular Outcomes in Nova Scotia (ICONS) study. Canadian Journal of Cardiology, 2003, 19, 439-44.	0.8	15
104	Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era?. Journal of the American College of Cardiology, 2002, 40, 1748-1754.	1.2	340
105	A qualitative study of evidence in primary care: what the practitioners are saying. Cmaj, 2002, 166, 1525-30	0.9	24
106	American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes ³¹ This document was approved by the American College of Cardiology Board of Trustees in November 2001. ³² When citing this document, the American College of Cardiology would appreciate the following citation format: Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, Every NR, Flaherty JT, Harrington RA, Krumholz HM, Simoons ML, Van de Werf FJ, Weintraub. Journal of the American College of Cardiology, 2001, 38, 2114-2	1.2	621
107	HRT to prevent cardiovascular disease. Postgraduate Medicine, 2000, 108, 59-72.	0.9	4
108	Title is missing!. Journal of Thrombosis and Thrombolysis, 1998, 5, S169-S175.	1.0	0

#	ARTICLE	IF	CITATIONS
109	On-site cardiac catheterization facilities were associated with more cardiac procedures but no difference in mortality. Evidence-based Cardiovascular Medicine, 1998, 2, 11.	0.0	0
110	Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Journal of the American College of Cardiology, 1998, 32, 634-640.	1.2	139
111	Managed delay for coronary artery bypass graft surgery: The experience at one Canadian center. Journal of the American College of Cardiology, 1996, 27, 1365-1373.	1.2	45
112	Limitations of canadian cardiovascular society classification of angina pectoris. American Journal of Cardiology, 1994, 74, 276-277.	0.7	18
113	Revascularization after acute myocardial infarction. Journal of General Internal Medicine, 1994, 9, 674-678.	1.3	15
114	Ethics of queuing for coronary artery bypass grafting in Canada. Cmaj, 1994, 151, 949-53.	0.9	2
115	Treatment of cardiac arrhythmias during pregnancy. Progress in Cardiovascular Diseases, 1993, 36, 137-178.	1.6	90
116	The Canadian Cardiovascular Society Grading Scale for Angina Pectoris: Is It Time for Refinements?. Annals of Internal Medicine, 1992, 117, 677-683.	2.0	67
117	Cardiovascular manifestations of Lyme disease. American Heart Journal, 1991, 122, 1449-1455.	1.2	90
118	Stranger in a strange land: The pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Progress in Cardiovascular Diseases, 1991, 34, 45-68.	1.6	307
119	The Background to the Syrian Campaign, May-June 1941: A study in Franco-German wartime relations. History, 1987, 72, 432-452.	0.0	1
120	A splendid training ground: The importance to the Royal air force of its role in Iraq, 1919â€“32. Journal of Imperial and Commonwealth History, 1985, 13, 157-184.	0.2	21